Company Financials
Poolbeg Pharma PLC Financials
Pound sterling
business
Poolbeg Pharma PLC Company Profile
Main Stock Listing
LSE: POLB
Market Capitalization £None as of Jan. 11, 2021
Market Cap History
Valuations Metrics as of May. 5, 2024
| Trailing PE | -1420.21 |
| Forward PE | -10.76 |
| Price to Sales TTM | £ |
| Price to Book MRQ | £387.88 |
| Enterprise to Revenue | |
| Enterprise to EBITDA | -8.28 |
Financial Reports as of Jun. 30, 2023
Financials
| Fiscal Year Ends | 2022-12-31 |
| Most Recent Quarter | 2023-06-30 |
| Profit Margin | 0.00% |
| Operating Margin | 0.00% |
| Return on Assets TTM | -24.29% |
| Return on Equity TTM | -25.57% |
Income Statement
| Revenue TTM | £0 |
| Revenue per Share TTM | £0.00 |
| Quarterly Revenue Growth | % |
| Gross Profit TTM | £0 |
| EBITDA | £-5,569,000 |
| Net Income to Common TTM | £-4,890,000 |
| Diluted EPS TTM | £-0.01 |
| Quarterly Earnings Growth YoY | % |
Balance Sheet
| Total Cash MRQ | £14,120,000 |
| Total Cash per Share MRQ | £0.03 |
| Total Debt MRQ | £ |
| Total Debt to Equity MRQ | 0.00 |
| Current Ratio MRQ | 29.13 |
| Book Value per Share MRQ | £0.03 |
Cash Flow
| Operating Cash Flow TTM | £-4,936,000 |
| Levered Free Cash Flow TTM | £-4,686,000 |
POLB Stock Info as of May. 5, 2024
Stock Statistics
| Shares Outstanding | 500,000,000 |
| Float Shares | 421,630,000 |
| Avg 10 Volume | 2,681,952 |
| Avg 30 Volume | None |
| Shares Short | None |
| Short Ratio | |
| Short % of Shares | % |
| % Held by Insiders | 22.66% |
| % Held by Institutions | 6.08% |
Stock Price Summary
| Beta | 2.26 |
| Fifty Two Week Low | £6.38 |
| Fifty Two Week High | £13.80 |
| Fifty Two Week Change | 47.19% |
| Day 50 MA | £10.02 |
| Day 200 MA | £8.62 |
Dividends and Splits
| Forward Annual Dividend Rate | £ |
| Forward Annual Dividend Yield | % |
| Trailing Annual Dividend Rate | £0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Payout Ratio | 0.00% |
| Dividend Date | |
| Ex Dividend Date | |
| Last Split Factor | |
| Last Split Date |